纳米晶纤维素-基尼化物复合物增强了肠-大脑轴调节,用于治疗抑郁症
Tianyu Zou1, Xiang Tang2, Haiping Wang2
1Department of Encephalopathy, Shenzhen Luohu District Hospital of Traditional Chinese Medicine (Shenzhen Hospital of Shanghai University of Traditional Chinese Medicine), Shenzhen, 518000, Guangdong, PR China. stevezou1986@hotmail.com.
Communications biology
|April 26, 2025
概括
这项研究表明,Geniposide (GP) 和纳米晶纤维素 (NCC) 复合物通过平衡肠道细菌和增强肠-大脑轴功能来改善抑郁症. 该复合物激活AMPK通路,促进BCL2表达并改善情绪.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抑郁症是一个全球性的健康问题,与肠道微生物群失调和肠道功能障碍有关.
- 肠-大脑轴在情绪调节中起着至关重要的作用,并与抑郁症病理生理学有关.
研究的目的:
- 为了研究基尼化物 (GP) 和纳米晶纤维素 (NCC) 复合物的抗抑郁作用.
- 探索复合物对肠-大脑轴及其潜在分子机制的影响.
主要方法:
- 网络药理学确定GP是针对抑郁症BCL2基因的关键化合物.
- 他们使用了一种慢性不可预测的轻度压力 (CUMS) 鼠标模型,细胞测试和便微生物群移植 (FMT).
- 该研究评估了复合物对肠道屏障完整性,肠道菌群和海马体功能的影响.
主要成果:
- 发现GP通过调高BCL2表达来激活AMPK通路.
- 该GP-NCC复合物增强了肠道屏障的完整性,并促进了肠道微生物群平衡.
- 用复合剂治疗减少了小鼠的抑郁类行为,并改善了海马体功能.
结论:
- 该GP-NCC复合体通过调节肠-大脑轴来证明抗抑郁药的潜力.
- 通过GP等化合物准肠道健康,为抑郁症治疗提供了一个有希望的策略.
- 这项研究强调了AMPK/BCL2途径在抑郁症管理中的治疗作用.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
173
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
173
Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109
G-protein Coupled Receptors
112.1K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
112.1K
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Antidepressant Drugs: MAOIs and Other Agents
160
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
160
Drugs for Treatment of Diarrhea-Predominant IBS
117
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
117


